DWTX vs. VRCA, TNYA, CUE, BLUE, RVPH, XLO, ATNM, SPRO, OSTX, and IRD
Should you be buying Dogwood Therapeutics stock or one of its competitors? The main competitors of Dogwood Therapeutics include Verrica Pharmaceuticals (VRCA), Tenaya Therapeutics (TNYA), Cue Biopharma (CUE), bluebird bio (BLUE), Reviva Pharmaceuticals (RVPH), Xilio Therapeutics (XLO), Actinium Pharmaceuticals (ATNM), Spero Therapeutics (SPRO), OS Therapies (OSTX), and Opus Genetics (IRD). These companies are all part of the "pharmaceutical products" industry.
Dogwood Therapeutics vs.
Dogwood Therapeutics (NASDAQ:DWTX) and Verrica Pharmaceuticals (NASDAQ:VRCA) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their community ranking, institutional ownership, profitability, media sentiment, earnings, risk, dividends, valuation and analyst recommendations.
Dogwood Therapeutics has a beta of 1.99, indicating that its share price is 99% more volatile than the S&P 500. Comparatively, Verrica Pharmaceuticals has a beta of 1.68, indicating that its share price is 68% more volatile than the S&P 500.
Dogwood Therapeutics has a net margin of 0.00% compared to Verrica Pharmaceuticals' net margin of -625.06%. Dogwood Therapeutics' return on equity of -217.12% beat Verrica Pharmaceuticals' return on equity.
Dogwood Therapeutics currently has a consensus price target of $10.00, indicating a potential upside of 82.48%. Verrica Pharmaceuticals has a consensus price target of $9.50, indicating a potential upside of 1,946.53%. Given Verrica Pharmaceuticals' higher probable upside, analysts plainly believe Verrica Pharmaceuticals is more favorable than Dogwood Therapeutics.
Dogwood Therapeutics has higher earnings, but lower revenue than Verrica Pharmaceuticals. Dogwood Therapeutics is trading at a lower price-to-earnings ratio than Verrica Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Verrica Pharmaceuticals received 166 more outperform votes than Dogwood Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Dogwood Therapeutics an outperform vote while only 63.26% of users gave Verrica Pharmaceuticals an outperform vote.
9.1% of Dogwood Therapeutics shares are owned by institutional investors. Comparatively, 42.5% of Verrica Pharmaceuticals shares are owned by institutional investors. 12.2% of Dogwood Therapeutics shares are owned by insiders. Comparatively, 42.6% of Verrica Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
In the previous week, Dogwood Therapeutics had 6 more articles in the media than Verrica Pharmaceuticals. MarketBeat recorded 8 mentions for Dogwood Therapeutics and 2 mentions for Verrica Pharmaceuticals. Verrica Pharmaceuticals' average media sentiment score of 1.87 beat Dogwood Therapeutics' score of 1.21 indicating that Verrica Pharmaceuticals is being referred to more favorably in the news media.
Summary
Verrica Pharmaceuticals beats Dogwood Therapeutics on 9 of the 16 factors compared between the two stocks.
Get Dogwood Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for DWTX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Dogwood Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:DWTX) was last updated on 5/1/2025 by MarketBeat.com Staff
